Peter P De Deyn

List of Publications by Year
in descending order

258 papers	19,670 citations	36203 51 h-index	13727 129 g-index
303 all docs	303 docs citations	303 times ranked	21904 citing authors

#	Article	IF	Citations
1	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
2	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	9.4	2,155
3	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
4	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
5	Applications of the Morris water maze in the study of learning and memory. Brain Research Reviews, 2001, 36, 60-90.	9.1	1,647
6	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
7	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
8	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. European Journal of Neuroscience, 2003, 17, 388-396.	1.2	244
9	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiology of Aging, 2008, 29, 1143-1159.	1.5	217
10	Immune hyperreactivity of Aβ plaque-associated microglia in Alzheimer's disease. Neurobiology of Aging, 2017, 55, 115-122.	1.5	205
11	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	1.1	201
12	Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. Neuron, 2019, 103, 702-718.e5.	3.8	198
13	Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 2004, 19, 115-126.	1.3	171
14	Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease. FASEB Journal, 2012, 26, 2811-2823.	0.2	166
15	Loss of *TBK1* is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology, 2015, 85, 2116-2125.	1.5	151
16	Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. BMJ Open, 2015, 5, e007454.	0.8	141
17	Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease. Journal of Clinical Psychopharmacology, 2005, 25, 463-467.	0.7	129
18	Eagle syndrome: A comprehensive review. Clinical Neurology and Neurosurgery, 2017, 159, 34-38.	0.6	129

#	Article	IF	Citations
19	PTZ-induced seizures in mice require a revised Racine scale. Epilepsy and Behavior, 2019, 95, 51-55.	0.9	129
20	Risk Factors for Poststroke Depression. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 147-158.	1.2	126
21	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. Lancet Neurology, The, 2015, 14, 814-822.	4.9	124
22	Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behavioural Brain Research, 2005, 162, 233-239.	1.2	117
23	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
24	Depression in Mild Cognitive Impairment is associated with Progression to Alzheimer's Disease: A Longitudinal Study. Journal of Alzheimer's Disease, 2014, 42, 1239-1250.	1.2	107
25	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. International Journal of Geriatric Psychiatry, 2005, 20, 1028-1037.	1.3	104
26	PROGRESS IN UREMIC TOXIN RESEARCH: Guanidino Compounds as Uremic (Neuro)Toxins. Seminars in Dialysis, 2009, 22, 340-345.	0.7	103
27	A 22â€‘single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid $A\beta_{42}$. Alzheimer's and Dementia, 2015, 11, 1452-1460.	0.4	96
28	Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story. Neurochemistry International, 2017, 102, 22-32.	1.9	95
29	A new glaucoma hypothesis: a role of glymphatic system dysfunction. Fluids and Barriers of the CNS, 2015, 12, 16.	2.4	93
30	Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial. Movement Disorders, 2000, 15, 1230-1237.	2.2	89
31	Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clinical Neurology and Neurosurgery, 2005, 107, 497-508.	0.6	88
32	Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. Neurobiology of Learning and Memory, 2006, 85, 164-172.	1.0	86
33	Clinical features of *TBK1* carriers compared with *C9orf72*, *GRN* and non-mutation carriers in a Belgian cohort. Brain, 2016, 139, 452-467.	3.7	86
34	Progranulin locus deletion in frontotemporal dementia. Human Mutation, 2008, 29, 53-58.	1.1	85
35	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 213-224.	3.9	83
36	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-Î² Isoforms for Early and Differential Dementia Diagnosis. Journal of Alzheimer's Disease, 2015, 45, 813-822.	1.2	82

#	Article	IF	Citations
37	The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Journal of Alzheimer's Disease, 2017, 60, 561-576.	1.2	82
38	Age‐and disease‐specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease. Journal of Neurochemistry, 2019, 151, 656-668.	2.1	81
39	The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. International Journal of Geriatric Psychiatry, 2005, 20, 70-79.	1.3	78
40	Neutrophil gelatinase-associated lipocalin: A novel inflammatory marker associated with late-life depression. Journal of Psychosomatic Research, 2013, 75, 444-450.	1.2	71
41	Sleep and Alzheimer's disease: A pivotal role for the suprachiasmatic nucleus. Sleep Medicine Reviews, 2018, 40, 17-27.	3.8	71
42	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2691-2700.	1.5	70
43	Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels. Alzheimer's and Dementia, 2014, 10, S290-8.	0.4	69
44	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. Neurobiology of Disease, 2015, 82, 526-539.	2.1	69
45	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. Acta Neuropathologica, 2018, 135, 827-837.	3.9	68
46	Dose dependent effect of APOE ε4 on behavioral symptoms in frontal lobe dementia. Neurobiology of Aging, 2006, 27, 285-292.	1.5	64
47	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiology of Aging, 2017, 51, 177.e9-177.e16.	1.5	60
48	The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results. BMC Neurology, 2014, 14, 254.	0.8	57
49	Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurology, 2017, 74, 445.	4.5	56
50	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 819-833.	1.2	53
51	Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. Clinical Chemistry, 2015, 61, 734-743.	1.5	53
52	Glymphatic stasis at the site of the lamina cribrosa as a potential mechanism underlying open‐angle glaucoma. Clinical and Experimental Ophthalmology, 2017, 45, 539-547.	1.3	53
53	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	3.9	53
54	Senescent Changes in Cerebrospinal Fluid Circulatory Physiology and Their Role in the Pathogenesis of Normal-tension Glaucoma. American Journal of Ophthalmology, 2013, 156, 5-14.e2.	1.7	52

#	ARTICLE	IF	CITATIONS
55	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	0.7	50
56	Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer's Disease. Frontiers in Neuroscience, 2019, 13, 49.	1.4	49
57	Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome. Neuroscience and Biobehavioral Reviews, 2014, 45, 72-84.	2.9	47
58	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 7.	3.0	47
59	Aripiprazole in the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2013, 14, 459-474.	0.9	46
60	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Molecular Neurodegeneration, 2015, 10, 30.	4.4	46
61	A complete pupillometry toolbox for real-time monitoring of locus coeruleus activity in rodents. Nature Protocols, 2020, 15, 2301-2320.	5.5	46
62	Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model.. Behavioral Neuroscience, 2008, 122, 491-497.	0.6	45
63	Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model. Journal of Neuroinflammation, 2018, 15, 330.	3.1	45
64	A multidisciplinary approach unravels early and persistent effects of X-ray exposure at the onset of prenatal neurogenesis. Journal of Neurodevelopmental Disorders, 2015, 7, 3.	1.5	44
65	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Frontiers in Neurology, 2015, 6, 138.	1.1	44
66	The Glymphatic System: A New Player in Ocular Diseases?. , 2016, 57, 5426.		42
67	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimer's Research and Therapy, 2018, 10, 31.	3.0	42
68	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. NeuroImage: Clinical, 2021, 31, 102712.	1.4	42
69	Functional Neural Correlates of Anosognosia in Mild Cognitive Impairment and Alzheimer's Disease: a Systematic Review. Neuropsychology Review, 2019, 29, 139-165.	2.5	41
70	Effects of Antiepileptic Drugs on GABA Responses and on Reduction of GABA Responses by PTZ and DMCM on Mouse Neurons in Cell Culture. Epilepsia, 1989, 30, 17-25.	2.6	39
71	Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochemistry International, 2005, 46, 409-422.	1.9	39
72	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. Journal of Alzheimer's Disease, 2016, 55, 763-776.	1.2	39

#	Article	IF	Citations
73	Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases. Ageing Research Reviews, 2021, 70, 101414.	5.0	39
74	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Journal of Alzheimer's Disease, 2018, 63, 797-819.	1.2	38
75	Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. Brain Research, 2011, 1378, 43-53.	1.1	37
76	Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimer's and Dementia, 2013, 9, 488-498.	0.4	37
77	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. Journal of Chromatography A, 2014, 1353, 28-39.	1.8	36
78	Overexpression of Arginase Alters Circulating and Tissue Amino Acids and Guanidino Compounds and Affects Neuromotor Behavior in Mice. Journal of Nutrition, 2001, 131, 2732-2740.	1.3	35
79	Prevalence and incidence of dementia among 75–80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: The Antwerp Cognition (ANCOG) Study. Clinical Neurology and Neurosurgery, 2011, 113, 736-745.	0.6	35
80	Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regulatory Peptides, 2009, 156, 77-82.	1.9	34
81	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	1.5	34
82	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Neuroscience Letters, 2016, 629, 160-164.	1.0	34
83	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 1079-1096.	1.2	33
84	Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies. PLoS ONE, 2019, 14, e0211000.	1.1	33
85	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. American Journal of Geriatric Psychiatry, 2020, 28, 735-744.	0.6	33
86	Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. International Journal of Geriatric Psychiatry, 2000, 15, S14-S22.	1.3	32
87	Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2014, 43, 871-891.	1.2	32
88	Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. NeuroImage, 2015, 109, 151-159.	2.1	32
89	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 768-788.	1.7	32
90	Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study. European Journal of Epidemiology, 2020, 35, 75-86.	2.5	32

#	Article	IF	Citations
91	Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placebo–controlled</scp>, <scp>double–blind</scp> phase I/Ib studies in healthy subjects and patients. Clinical and Translational Science, 2022, 15, 2010-2023.	1.5	31
92	Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. International Journal of Geriatric Psychiatry, 2015, 30, 864-869.	1.3	29
93	Phenotypic characteristics of Alzheimer patients carrying an <i>ABCA7</i> mutation. Neurology, 2016, 86, 2126-2133.	1.5	29
94	Alzheimer's disease: Neurotransmitters of the sleep-wake cycle. Neuroscience and Biobehavioral Reviews, 2019, 105, 72-80.	2.9	29
95	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 1-10.	1.2	28
96	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 309-320.	1.2	27
97	Investigating the Natural Course and Treatment of Vascular Dementia and Alzheimer's Disease: Parallel Study Populations in Two Randomized, Placebo-Controlled Trials. Annals of the New York Academy of Sciences, 2000, 903, 535-541.	1.8	26
98	Validation of the AD-CSF-Index in Autopsy-Confirmed Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2014, 41, 903-909.	1.2	26
99	Risperidone in the management of agitation and aggression associated with psychiatric disorders. European Psychiatry, 2006, 21, 21-28.	0.1	24
100	Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis. Vascular Pharmacology, 2019, 113, 70-76.	1.0	24
101	Glaucoma Considered as an Imbalance Between Production and Clearance of Neurotoxins. , 2014, 55, 5351.		23
102	PET Agents in Dementia: An Overview. Seminars in Nuclear Medicine, 2021, 51, 196-229.	2.5	23
103	Sex-specific associations between Neutrophil Gelatinase-Associated Lipocalin (NGAL) and cognitive domains in late-life depression. Psychoneuroendocrinology, 2014, 48, 169-177.	1.3	20
104	Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis. Journal of Immunology, 2014, 193, 2147-2156.	0.4	20
105	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 97-106.	1.2	20
106	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. MethodsX, 2015, 2, 112-123.	0.7	19
107	Accelerated high-frequency repetitive transcranial magnetic stimulation enhances motor activity in rats. Neuroscience, 2017, 347, 103-110.	1.1	19
108	Optic Nerve Sheath Distention as a Protective Mechanism Against the Visual Impairment and Intracranial Pressure Syndrome in Astronauts. , 2017, 58, 4601.		19

#	Article	IF	Citations
109	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	1.5	19
110	Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimerâ€™s disease. EJNMMI Research, 2019, 9, 59.	1.1	19
111	Associating Alzheimerâ€™s disease pathology with its cerebrospinal fluid biomarkers. Brain, 2022, 145, 4056-4064.	3.7	19
112	Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. Neurobiology of Aging, 2018, 69, 292.e7-292.e14.	1.5	18
113	Lower Choline and Myo-Inositol in Temporo-Parietal Cortex Is Associated With Apathy in Amnestic MCI. Frontiers in Aging Neuroscience, 2018, 10, 106.	1.7	18
114	Sleep architecture changes in the APP23 mouse model manifest at onset of cognitive deficits. Behavioural Brain Research, 2019, 373, 112089.	1.2	18
115	Differentiation Between Dementia and Depression Among Older Persons: Can the Difference Between Actual and Premorbid Intelligence Be Useful?. Journal of Geriatric Psychiatry and Neurology, 2008, 21, 242-249.	1.2	17
116	Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. Journal of Alzheimer's Disease, 2015, 45, 733-743.	1.2	17
117	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. Neurobiology of Aging, 2018, 67, 84-94.	1.5	17
118	Inducing Physical Inactivity in Mice: Preventing Climbing and Reducing Cage Size Negatively Affect Physical Fitness and Body Composition. Frontiers in Behavioral Neuroscience, 2019, 13, 221.	1.0	17
119	Iron chelators inhibit amyloid-β-induced production of lipocalin 2 in cultured astrocytes. Neurochemistry International, 2020, 132, 104607.	1.9	17
120	Comparison of extraction methods for peptidomics analysis of mouse brain tissue. Journal of Neuroscience Methods, 2011, 197, 231-237.	1.3	16
121	Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. International Journal of Geriatric Psychiatry, 2012, 27, 296-304.	1.3	16
122	Intracranial pressure-induced optic nerve sheath response as a predictive biomarker for optic disc edema in astronauts. Biomarkers in Medicine, 2017, 11, 1003-1008.	0.6	16
123	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 172-181.	1.2	16
124	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	1.5	16
125	The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy. Medical Hypotheses, 2018, 118, 142-145.	0.8	16
126	Glaucoma and the Role of Cerebrospinal Fluid Dynamics. , 2015, 56, 6630.		15

#	Article	IF	Citations
127	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. Journal of Alzheimer's Disease, 2015, 45, 1039-1043.	1.2	15
128	Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture. Physiology and Behavior, 2015, 139, 397-402.	1.0	15
129	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Acta Neurologica Belgica, 2017, 117, 811-819.	0.5	15
130	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
131	Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. Journal of Alzheimer's Disease, 2019, 69, 1019-1030.	1.2	15
132	Functional network topology associated with apathy in Alzheimer's disease. Journal of Affective Disorders, 2020, 266, 473-481.	2.0	15
133	Functional connectivity differences in Alzheimer's disease and amnestic mild cognitive impairment associated with AT(N) classification and anosognosia. Neurobiology of Aging, 2021, 101, 22-39.	1.5	15
134	A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer's Disease Studies. Frontiers in Psychiatry, 2022, 13, 879491.	1.3	15
135	Evaluation of the APP23-model for Alzheimer's disease in the odour paired-associate test for hippocampus-dependent memory. Behavioural Brain Research, 2008, 190, 147-151.	1.2	14
136	Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. Neuroscience Letters, 2009, 463, 93-97.	1.0	14
137	Validation assessment of risk tools to predict outcome after thrombolytic therapy for acute ischemic stroke. Clinical Neurology and Neurosurgery, 2014, 125, 189-193.	0.6	14
138	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. Neurobiology of Disease, 2017, 105, 235-244.	2.1	14
139	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. Journal of Alzheimer's Disease, 2019, 69, 989-1001.	1.2	14
140	Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. Vascular Pharmacology, 2019, 118-119, 106561.	1.0	14
141	Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient. Neurochemistry International, 2019, 128, 154-162.	1.9	14
142	Kinetics and 28-day test–retest repeatability and reproducibility of [^{11}C]UCB-J PET brain imaging. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1338-1350.	2.4	14
143	Widespread white matter aberration is associated with the severity of apathy in amnestic Mild Cognitive Impairment: Tract-based spatial statistics analysis. NeuroImage: Clinical, 2021, 29, 102567.	1.4	14
144	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation1. Journal of Alzheimer's Disease, 2021, 81, 1505-1527.	1.2	14

#	Article	IF	Citations
145	The neglected puzzle of dementia in people with severe/profound intellectual disabilities: A systematic literature review of observable symptoms. Journal of Applied Research in Intellectual Disabilities, 2022, 35, 24-45.	1.3	14
146	How well do people living with neurodegenerative diseases manage their finances? A meta-analysis and systematic review on the capacity to make financial decisions in people living with neurodegenerative diseases. Neuroscience and Biobehavioral Reviews, 2021, 127, 709-739.	2.9	14
147	Age-related cognitive decline in spatial learning and memory of C57BL/6J mice. Behavioural Brain Research, 2022, 418, 113649.	1.2	14
148	Nutritional interventions in community-dwelling Alzheimer patients with (risk of) undernutrition: a systematic review. International Psychogeriatrics, 2014, 26, 1445-1453.	0.6	13
149	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathologica Communications, 2015, 3, 68.	2.4	13
150	EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2016, 55, 53-58.	1.2	13
151	The Relationship of Coronary Artery Calcium and Clinical Coronary Artery Disease with Cognitive Function: A Systematic Review and Meta-Analysis. Journal of Atherosclerosis and Thrombosis, 2020, 27, 934-958.	0.9	13
152	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 108, 99-109.	1.5	13
153	Crossed Cerebellar Diaschisis in Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 1267-1275.	0.7	13
154	Animal models of human disorders?general aspects. Neuroscience Research Communications, 2000, 26, 141-148.	0.2	12
155	Headache As Only Symptom in Multiple Cervical Artery Dissection. Headache, 2001, 41, 509-511.	1.8	12
156	Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease. International Psychogeriatrics, 2015, 27, 1323-1333.	0.6	12
157	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. Journal of Parkinson's Disease, 2018, 8, 71-84.	1.5	12
158	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. Journal of Alzheimer's Disease, 2018, 63, 373-381.	1.2	12
159	Pentylenetetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of Tauopathy. Neuroscience, 2020, 425, 112-122.	1.1	12
160	Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. Neurochemical Research, 2020, 45, 1191-1201.	1.6	12
161	Pain processing in older adults with dementia-related cognitive impairment is associated with frontal neurodegeneration. Neurobiology of Aging, 2021, 106, 139-152.	1.5	12
162	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 107, 1-10.	1.5	12

#	Article	IF	Citations
163	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	1.9	12
164	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 105-112.	1.8	11
165	No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimer's Research and Therapy, 2017, 9, 49.	3.0	11
166	Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?. Medical Hypotheses, 2018, 118, 98-102.	0.8	11
167	Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6656.	1.8	11
168	Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. Neuroscience Research Communications, 2000, 26, 193-206.	0.2	10
169	The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimerâ€™s disease: results from a cohort study. Alzheimer's Research and Therapy, 2015, 7, 18.	3.0	10
170	The Possible Role of Elastic Properties of the Brain and Optic Nerve Sheath in the Development of Spaceflight-Associated Neuro-Ocular Syndrome. American Journal of Neuroradiology, 2020, 41, E14-E15.	1.2	10
171	Dementia in people with severe or profound intellectual (and multiple) disabilities: Focus group research into relevance, symptoms and training needs. Journal of Applied Research in Intellectual Disabilities, 2021, 34, 1602-1617.	1.3	10
172	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. Neurobiology of Aging, 2021, 106, 307.e1-307.e7.	1.5	10
173	Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 395-405.	1.8	9
174	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 99-111.	1.2	9
175	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	0.5	9
176	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Journal of Alzheimer's Disease, 2019, 68, 1151-1159.	1.2	9
177	Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice. Neurobiology of Disease, 2020, 143, 105011.	2.1	9
178	The role of low intracranial pressure in the development of glaucoma in patients with Alzheimer's disease. Progress in Retinal and Eye Research, 2014, 39, 107-110.	7.3	8
179	Subtle alterations in cerebrovascular reactivity in mild cognitive impairment detected by graph theoretical analysis and not by the standard approach. NeuroImage: Clinical, 2017, 15, 151-160.	1.4	8
180	Adapted Morris Water Maze protocol to prevent interference from confounding motor deficits on cognitive functioning. Somatosensory & Motor Research, 2017, 34, 172-178.	0.4	8

#	Article	IF	Citations
181	Temporal dynamics of depression, cognitive performance and sleep in older persons with depressive symptoms and cognitive impairments: a series of eight single-subject studies. International Psychogeriatrics, 2022, 34, 47-59.	0.6	8
182	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. Neurobiology of Aging, 2021, 104, 105.e1-105.e6.	1.5	8
183	Short- and Long-Term Functional Connectivity Differences Associated with Alzheimer's Disease Progression. Dementia and Geriatric Cognitive Disorders Extra, 2022, 11, 235-249.	0.6	8
184	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. Toxicology Letters, 2022, 356, 89-99.	0.4	8
185	Episodic memory in mild cognitive impairment inversely correlates with the global modularity of the cerebral blood flow network. Psychiatry Research - Neuroimaging, 2018, 282, 73-81.	0.9	7
186	Alzheimer's disease and glaucoma: Look–alike neurodegenerative diseases. Alzheimer's and Dementia, 2019, 15, 600-601.	0.4	7
187	Optimization of the k2′ Parameter Estimation for the Pharmacokinetic Modeling of Dynamic PIB PET Scans Using SRTM2. Frontiers in Physics, 2019, 7, .	1.0	7
188	The Anaesthetic Biobank of Cerebrospinal fluid: a unique repository for neuroscientific biomarker research. Annals of Translational Medicine, 2021, 9, 455-455.	0.7	7
189	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. Journal of Alzheimer's Disease, 2021, 83, 623-639.	1.2	7
190	Data modelling in corpus linguistics: How low may we go?. Cortex, 2014, 55, 192-201.	1.1	6
191	Evaluating the applicability of mouse SINEs as an alternative normalization approach for RT-qPCR in brain tissue of the APP23 model for Alzheimer's disease. Journal of Neuroscience Methods, 2019, 320, 128-137.	1.3	6
192	The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy. PLoS ONE, 2019, 14, e0210567.	1.1	6
193	Bioethical implications of end-of-life decision-making in patients with dementia: a tale of two societies. Monash Bioethics Review, 2020, 38, 49-67.	0.4	6
194	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	2.4	6
195	Animal use in experimental neuropathology: Provisions for animal welfare and ethics. Neuroscience Research Communications, 2000, 26, 149-160.	0.2	5
196	The squares test as a measure of hand function in multiple sclerosis. Clinical Neurology and Neurosurgery, 2014, 123, 55-60.	0.6	5
197	Coronary Artery Calcium and Cognitive Function in Dutch Adults: Cross–Sectional Results of the Population–Based ImaLife Study. Journal of the American Heart Association, 2021, 10, e018172.	1.6	5
198	Amyloid burden quantification depends on PET and MR image processing methodology. PLoS ONE, 2021, 16, e0248122.	1.1	5

#	ARTICLE	IF	CITATIONS
199	Dynamics of neutrophil gelatinaseâ€associated lipocalin plasma and cerebrospinal fluid concentrations in older males. European Journal of Clinical Investigation, 2017, 47, e12853.	1.7	4
200	Fibromyalgia as a glymphatic overload syndrome. Medical Hypotheses, 2018, 115, 17-18.	0.8	4
201	Clinical Considerations in Physician-Assisted Death for Probable Alzheimerâ€™s Disease: Decision-Making Capacity, Anosognosia, and Suffering. Dementia and Geriatric Cognitive Disorders Extra, 2019, 9, 217-226.	0.6	4
202	Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. NeuroImage: Clinical, 2021, 30, 102625.	1.4	4
203	Alzheimerâ€™s disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM/PCA. EJNMMI Research, 2022, 12, .	1.1	4
204	Risperidone in the Treatment of Behavioral and Psychological Symptoms of Dementia. International Psychogeriatrics, 2000, 12, 263-269.	0.6	3
205	Serum Glutamine Synthetase Has No Value as a Diagnostic Biomarker for Alzheimerâ€™s Disease. Neurochemical Research, 2011, 36, 1858-1862.	1.6	3
206	Uptake and effectiveness of a tailor-made online lifestyle programme targeting modifiable risk factors for dementia among middle-aged descendants of people with recently diagnosed dementia: study protocol of a cluster randomised controlled trial (Demin study). BMJ Open, 2020, 10, e039439.	0.8	3
207	Practices and opinions about disclosure of the diagnosis of Alzheimerâ€™s disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. Acta Neurologica Belgica, 2020, 120, 1157-1163.	0.5	3
208	Chronic adolescent stress increases exploratory behavior but does not appear to change the acute stress response in adult male C57BL/6 mice. Neurobiology of Stress, 2021, 15, 100388.	1.9	3
209	Validation and testâ€"retest repeatability performance of parametric methods for [11C]UCB-J PET. EJNMMI Research, 2022, 12, 3.	1.1	3
210	Dilated Virchow-Robin spaces in primary open-angle glaucoma: a biomarker of glymphatic waste clearance dysfunction?. Acta Radiologica Open, 2016, 5, 205846011665363.	0.3	2
211	A familyâ€based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. Alzheimer's and Dementia, 2020, 16, e047212.	0.4	2
212	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. Neurobiology of Aging, 2021, 97, 145.e1-145.e4.	1.5	2
213	Altered stress hormone levels affect in vivo vascular function in the hAPP23+/- overexpressing mouse model of Alzheimer's disease. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H905-H919.	1.5	2
214	A new look at glaucoma. Journal of Ophthalmic and Vision Research, 2015, 10, 502.	0.7	2
215	NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model. Peptides, 2009, 30, 2480-2482.	1.2	1
216	Could ecosystem management provide a new framework for Alzheimer's disease?. Alzheimer's and Dementia, 2016, 12, 65.	0.4	1

#	Article	IF	Citations
217	"Hypodense Holes"and the Ocular Glymphatic System: Author Response: "Black Holes"and the Ocular Glymphatic System. , 2017, 58, 1132.		1
218	Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?. Medical Hypotheses, 2018, 118, 174.	0.8	1
219	The retinal nerve fiber layer as a window to the glymphatic system. Clinical Neurology and Neurosurgery, 2020, 188, 105593.	0.6	1
220	Animal models of human disorders—general aspects. , 2000, 26, 141.		1
221	Planning in amnestic mild cognitive impairment: an fMRI study. Experimental Gerontology, 2022, 159, 111673.	1.2	1
222	Plasma 5-HIAA activity indicative of serotonergic disturbances in cognitively impaired, elderly patients experiencing postoperative delirium. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	1
223	Short-Term Pharmacological Induction of Arterial Stiffness and Hypertension with Angiotensin II Does Not Affect Learning and Memory and Cerebral Amyloid Load in Two Murine Models of Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 2738.	1.8	1
224	Dementia in People with Severe/Profound Intellectual (and Multiple) Disabilities: Practice-Based Observations of Symptoms. Journal of Mental Health Research in Intellectual Disabilities, 2022, 15, 364-393.	1.3	1
225	Drug Treatment: Treatment of Behavioural and Psychological Symptoms of Dementia with Neuroleptics. , 2006, , 151-162.		0
226	O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease. , 2010, 6, S73-S74.		0
227	P1-053: OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE. , 2014, 10, P322-P323.		0
228	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
229	O4-11-03: Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer's disease. , 2015, 11, P296-P297.		0
230	P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients. , 2015, 11, P626-P626.		0
231	P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease. , 2015, 11, P854-P854.		0
232	P1-176: CSF Exploratory Biomarker Study for (DIFFERENTIAL) Diagnosis of Frontotemporal Lobar Degeneration. Alzheimer's and Dementia, 2016, 12, P471.	0.4	0
233	P2-153: Diagnostic Performance of Non-Phosphorylated TAU Fraction (PTAU REL) in CSF as Biomarker for Differential Dementia Diagnosis. , 2016, 12, P672-P673.		0
234	P4-120: Increased CSF Levels of Biomarkers for Neurodegeneration in FTLD-GRN Mutation Carriers. Alzheimer's and Dementia, 2016, 12, P1058.	0.4	0

#	Article	IF	Citations
235	O4â€09â€03: Eeg Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. Alzheimer's and Dementia, 2016, 12, P354.	0.4	0
236	P1â€156: Abeta Plaqueâ€Associated Microglia Priming in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P462.	0.4	0
237	P1-170: A Decade of Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease in Belgium. , 2016, 12, P467-P468.		0
238	P4â€314: Discordance Between Amyloidâ€PET and CSF Amyloidâ€Î² for Diagnosing Alzheimerâ€™S Disease in a Clinical Setting. Alzheimer's and Dementia, 2016, 12, P1154.	0.4	0
239	P4â€322: CSF Biomarkers to Predict Rate of Cognitive Decline in Alzheimerâ€™S Disease. Alzheimer's and Dementia, 2016, 12, P1157.	0.4	0
240	[P4â€"069]: A PROSPECTIVE NEUROGENETIC STUDY ON EARLYâ€ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1284.	0.4	0
241	[P2â€"387]: EPISODIC MEMORY IN MILD COGNITIVE IMPAIRMENT INVERSELY CORRELATES WITH THE PATIENT CONTRIBUTION TO CEREBRAL BLOOD FLOW NETWORK MODULARITY. Alzheimer's and Dementia, 2017, 13, P777.	0.4	0
242	[P3â€"307]: RESTING STATE CONNECTIVITY RELATED TO APATHY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1064.	0.4	0
243	[P4â€"174]: THE ASSOCIATION BETWEEN APATHY AND COGNITIVE FUNCTION IN AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1329.	0.4	0
244	[P2â€"116]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P651.	0.4	0
245	O4â€01â€01: INâ€DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1400.	0.4	0
246	P3â€128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1116.	0.4	0
247	P3â€307: THE ASSOCIATION BETWEEN APATHY AND STRUCTURAL BRAIN ALTERATIONS IN AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1199.	0.4	0
248	Intrathecal cerebrospinal fluid infusion as a potential therapeutic strategy for Alzheimerâ€™s disease. Medical Hypotheses, 2019, 122, 57.	0.8	0
249	P1â€291: THE ASSOCIATION BETWEEN AFFECTIVE SYMPTOMS AND ALZHEIMER'S DISEASE BIOMARKERS ACROSS THE DISEASE SPECTRUM. Alzheimer's and Dementia, 2019, 15, P355.	0.4	0
250	Recessive missense variants in VWA2 increase risk of developing Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039791.	0.4	0
251	ABCA7 mutations are major contributors to Alzheimerâ€™s disease in Belgian patients. Alzheimer's and Dementia, 2020, 16, e040227.	0.4	0
252	Apathy and white matter integrity in amnestic mild cognitive impairment: A whole brain analysis with tractâ€based spatial statistics. Alzheimer's and Dementia, 2020, 16, e040838.	0.4	0

#	Article	IF	Citations
253	ABCA7 PTC mutation carriers present with Alzheimerâ€™s disease pathology and cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e041513.	0.4	0
254	Knowledge, beliefs and attitudes towards dementia risk assessment and reduction among individuals with a parental family history of dementia. Alzheimer's and Dementia, 2020, 16, e042533.	0.4	0
255	Demin: Design and baseline results of a cluster randomized controlled trial investigating the uptake and effectiveness of a dementia risk reduction program in middleâ€aged descendants of people with recently diagnosed Alzheimer disease or vascular dementia. Alzheimer's and Dementia, 2020, 16, e042609.	0.4	0
256	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
257	Levels of circulating memory CD8 T cells that induce ADâ€like pathology in mice correlate with cognition and decreased CSF AÎ²1â€42 in AD and control patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
258	Neural correlates of executive functions in people with amnestic mild cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0